# Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

> **NCT05225259** · — · NO_LONGER_AVAILABLE · sponsor: **Eli Lilly and Company**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Thyroid Neoplasms

## Interventions

- **DRUG:** LOXO-260

## Key facts

- **NCT ID:** NCT05225259
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05225259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05225259, "Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05225259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*